In this study, we aimed to explore: (1) the associations of plasma Aβ40, Aβ42, and tau protein levels with cognitive presentations around 3 months after first-ever ischemic stroke; and (2) the relationships of plasma Aβ40, Aβ42, and tau protein with the relevant imaging markers, such as cortical atrophy on MRI and amyloid burden on PET imaging. The gene discussed is MAPT; the disease is amyloidosis.